Neuromedin N inhibitors are a class of chemical compounds designed to specifically target and modulate the action of neuromedin N, a neuropeptide that plays a pivotal role in various physiological processes within the body. Neuromedin N is primarily involved in the regulation of smooth muscle contraction, particularly in the gastrointestinal tract, and it also has implications in regulating the central nervous system. This neuropeptide functions by binding to specific G protein-coupled receptors (GPCRs), activating intracellular signaling pathways that influence muscle tone, motility, and neuronal signaling. By understanding the mechanisms through which neuromedin N operates, researchers can identify and synthesize inhibitors that disrupt this signaling cascade.
The development of neuromedin N inhibitors typically involves a multifaceted approach, beginning with high-throughput screening methods to identify small molecules or peptides capable of selectively binding to the receptors that neuromedin N activates. Structural studies, such as crystallography or NMR spectroscopy, provide insights into the interactions between the neuropeptide and its receptors, which can inform the design of potent inhibitors. These inhibitors aim to block the biological effects of neuromedin N by preventing its binding to its receptors or interfering with the subsequent signaling pathways. Research into this class of inhibitors contributes to a deeper understanding of the physiological roles of neuromedin N, including its effects on smooth muscle dynamics and neuronal communication, and sheds light on the complex interplay of neuropeptides in the body's regulatory systems. As scientists continue to explore the intricacies of neuromedin N signaling, the inhibitors developed may pave the way for novel insights into neuropeptide biology and its broader implications in physiology.
SEE ALSO...
Items 11 to 12 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
Rosiglitazone, through activation of PPARγ, could repress the transcriptional machinery required for Neuromedin N gene expression, leading to lower peptide levels. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $182.00 $661.00 | 10 | |
Chetomin disrupts the interaction between HIF-1 and coactivators, potentially leading to a decrease in HIF-1-induced Neuromedin N expression under hypoxic conditions. | ||||||